Shots:

• The P-III MOUNTAIN study involves assessing of SAGE-217 (20/ 30mg) vs PBO in 581 patients with MDD
• The P-III MOUNTAIN study results: did not meet its 1EP i.e- reduction in 17-item HAM-D score @15days; SAGE-217 (30mg) showed mean reduction in HAM-D (12.6 vs 11.2); reduction in HAM-D@3- 8 &12days; safe & well tolerated. Patients showed significant improvement in previous studies i.e- (HAM-D>24)
• SAGE-217 (PO) is a neuroactive steroid (NAS) GABA_A receptor positive allosteric modulator- being evaluated in 5 studies out of which two reported positive data in MDD and PPD

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Behance